Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sintilimab Plus Bevacizumab in Patients With Recurrent/Persistent Ovarian Clear Cell Carcinoma

NCT04735861 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT04735861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04735861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sintilimab Plus Bevacizumab in Patients With Recurrent/Persistent Ovarian Clear Cell Carcinoma
Lead sponsor
Tongji Hospital
Phase
Phase 2
Overall status
Completed
Start date
April 7, 2021
Completion date
July 30, 2024
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian clear cell carcinoma